231 related articles for article (PubMed ID: 36735214)
21. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
23. Therapy of atopic eczema.
Werfel T; Claes C; Kulp W; Greiner W; von der Schulenburg JM
GMS Health Technol Assess; 2006 Oct; 2():Doc19. PubMed ID: 21289970
[TBL] [Abstract][Full Text] [Related]
24. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.
Kapp A; Papp K; Bingham A; Fölster-Holst R; Ortonne JP; Potter PC; Gulliver W; Paul C; Molloy S; Barbier N; Thurston M; de Prost Y;
J Allergy Clin Immunol; 2002 Aug; 110(2):277-84. PubMed ID: 12170269
[TBL] [Abstract][Full Text] [Related]
25. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
26. Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.
Yang LP; Curran MP
Paediatr Drugs; 2009; 11(6):407-26. PubMed ID: 19877726
[TBL] [Abstract][Full Text] [Related]
27. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
29. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
Werfel T
J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
31. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
Reitamo S; Remitz A; Kyllönen H; Saarikko J
Am J Clin Dermatol; 2002; 3(6):381-8. PubMed ID: 12113647
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.
Abędź N; Pawliczak R
Postepy Dermatol Alergol; 2019 Dec; 36(6):752-759. PubMed ID: 31998006
[TBL] [Abstract][Full Text] [Related]
34. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
El-Batawy MM; Bosseila MA; Mashaly HM; Hafez VS
J Dermatol Sci; 2009 May; 54(2):76-87. PubMed ID: 19303745
[TBL] [Abstract][Full Text] [Related]
35. Position statement: topical calcineurin inhibitors in atopic dermatitis.
Remitz A; De Pità O; Mota A; Serra-Baldrich E; Vakirlis E; Kapp A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2074-2082. PubMed ID: 30288799
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis.
Yin ZQ; Zhang WM; Song GX; Luo D
J Dermatol; 2012 Jun; 39(6):520-6. PubMed ID: 22409418
[TBL] [Abstract][Full Text] [Related]
37. Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling.
Shin N; Jung N; Lee SE; Kong D; Kim NG; Kook MG; Park H; Choi SW; Lee S; Kang KS
Stem Cell Res Ther; 2021 Aug; 12(1):482. PubMed ID: 34454603
[TBL] [Abstract][Full Text] [Related]
38. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
[TBL] [Abstract][Full Text] [Related]
39. Off-label Uses of Topical Pimecrolimus.
Ladda M; Sandhu V; Ighani A; Yeung J
J Cutan Med Surg; 2019; 23(4):442-448. PubMed ID: 31053034
[TBL] [Abstract][Full Text] [Related]
40. Topical therapy of atopic dermatitis with a focus on pimecrolimus.
Luger T; Paller AS; Irvine AD; Sidbury R; Eichenfield LF; Werfel T; Bieber T
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1505-1518. PubMed ID: 33834524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
